Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MOR Stock Summary
Top 10 Correlated ETFs
MOR
In the News
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.
MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?
Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?
Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline
Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer treatments.
Novartis to buy cancer drug maker MorphoSys for €2.7 billion
Novartis AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal. Unveiling the takeover on Monday, Novartis said the move would expand its oncology pipeline, relating to cancer treatments, alongside widening its footprint in haematology - blood disease studies.
Novartis to bolster its oncology portfolio with acquisition of MorphoSys
Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).
Novartis acquiring cancer drug developer Morphosys for €2.7 billion
CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.
Novartis acquires cancer drug developer MorphoSys for $2.9 bln
Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)
Why Is MorphoSys (MOR) Stock Up 50% Today?
Deal flow appears to be picking up, particularly in the world of big pharma and biotech stocks. MorphoSys (NASDAQ: MOR ) is the latest company to be reportedly in talks with Novartis (NYSE: NVS ) in a deal that would see its cancer drug portfolio rolled under Novartis' massive umbrella.
MOR Financial details
MOR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.57 | 2.47 | 1.34 | 2.04 | 1.74 | |
Net income per share | -0.81 | 0.74 | -3.85 | -1.11 | -1.38 | |
Operating cash flow per share | -0.63 | 0.27 | -3.6 | -2.68 | -2.16 | |
Free cash flow per share | -0.66 | -0.11 | -3.8 | -2.8 | -2.18 | |
Cash per share | 2.16 | 8.22 | 7.44 | 6.64 | 4.97 | |
Book value per share | 3.12 | 4.68 | 1.83 | 1.15 | 0.36 | |
Tangible book value per share | 2.77 | 4.15 | -6.95 | -7.94 | -8.29 | |
Share holders equity per share | 3.12 | 4.68 | 1.83 | 1.15 | 0.36 | |
Interest debt per share | 0.35 | 3.12 | 3.8 | 3.34 | 5.43 | |
Market cap | 4.01B | 3.08B | 1.11B | 458.44M | 1.23B | |
Enterprise value | 4.01B | 3.28B | 1.31B | 395.55M | 1.71B | |
P/E ratio | -38.9 | 31.42 | -2.16 | -3.03 | -6.48 | |
Price to sales ratio | 55.85 | 9.39 | 6.19 | 1.65 | 5.16 | |
POCF ratio | -50.01 | 87.2 | -2.31 | -1.25 | -4.16 | |
PFCF ratio | -47.82 | -218.64 | -2.19 | -1.2 | -4.12 | |
P/B Ratio | 10.15 | 4.95 | 4.54 | 2.91 | 25.06 | |
PTB ratio | 10.15 | 4.95 | 4.54 | 2.91 | 25.06 | |
EV to sales | 55.82 | 10.02 | 7.32 | 1.42 | 7.16 | |
Enterprise value over EBITDA | -40.51 | 25.71 | -7.33 | 2.29 | -17.46 | |
EV to operating cash flow | -49.98 | 93.11 | -2.73 | -1.08 | -5.77 | |
EV to free cash flow | -47.8 | -233.46 | -2.59 | -1.04 | -5.71 | |
Earnings yield | -0.03 | 0.03 | -0.46 | -0.33 | -0.15 | |
Free cash flow yield | -0.02 | 0 | -0.46 | -0.83 | -0.24 | |
Debt to equity | 0.11 | 0.51 | 1.33 | 2.16 | 12.97 | |
Debt to assets | 0.09 | 0.19 | 0.13 | 0.14 | 0.31 | |
Net debt to EBITDA | 0.02 | 1.63 | -1.13 | -0.36 | -4.88 | |
Current ratio | 4.93 | 6.02 | 3.98 | 3.91 | 3.08 | |
Interest coverage | -46.26 | 1.24 | -1.53 | 1.39 | -2.3 | |
Income quality | 0.78 | 0.36 | 0.94 | 2.43 | 1.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.51 | 0.16 | 0.44 | 0.3 | 0.36 | |
Research and developement to revenue | 1.51 | 0.43 | 1.25 | 1.07 | 1.19 | |
Intangibles to total assets | 0.09 | 0.04 | 0.46 | 0.52 | 0.59 | |
Capex to operating cash flow | 0.05 | -1.4 | 0.05 | 0.04 | 0.01 | |
Capex to revenue | -0.05 | -0.15 | -0.15 | -0.05 | -0.01 | |
Capex to depreciation | -0.59 | -5.92 | -2.59 | -1.45 | -0.27 | |
Stock based compensation to revenue | 0.09 | 0.03 | 0.01 | 0.01 | 0.11 | |
Graham number | 7.56 | 8.82 | 12.6 | 5.35 | 3.33 | |
ROIC | -0.21 | 0.53 | -0.39 | -2.58 | -0.36 | |
Return on tangible assets | -0.23 | 0.06 | -0.37 | -0.13 | -0.23 | |
Graham Net | 1.47 | 0.94 | -9.3 | -9.05 | -8.97 | |
Working capital | 242.13M | 1.01B | 848.43M | 810.69M | 549.71M | |
Tangible asset value | 349.9M | 550.33M | -929.02M | -1.09B | -1.14B | |
Net current asset value | 201.96M | 168.63M | -1.18B | -1.15B | -1.16B | |
Invested capital | 0.11 | 0.51 | 1.33 | 2.16 | 12.97 | |
Average receivables | 19.19M | 55.09M | 87.81M | 99.07M | 77.5M | |
Average payables | 8.94M | 29.11M | 60.67M | 56.18M | 33.48M | |
Average inventory | 266.69K | 5.13M | 15.36M | 22.5M | 43.16M | |
Days sales outstanding | 103.47 | 100.06 | 174.35 | 147.37 | 65.34 | |
Days payables outstanding | 321.8 | 1.89K | 836.41 | 289.62 | 177.56 | |
Days of inventory on hand | 8.7 | 396.37 | 235.27 | 182.07 | 388.22 | |
Receivables turnover | 3.53 | 3.65 | 2.09 | 2.48 | 5.59 | |
Payables turnover | 1.13 | 0.19 | 0.44 | 1.26 | 2.06 | |
Inventory turnover | 41.93 | 0.92 | 1.55 | 2 | 0.94 | |
ROE | -0.26 | 0.16 | -2.1 | -0.96 | -3.87 | |
Capex per share | -0.03 | -0.37 | -0.2 | -0.11 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.6 | 0.46 | 0.39 | 0.47 | 1.57 | |
Net income per share | 2.41 | -0.32 | -0.54 | -0.88 | 1.28 | |
Operating cash flow per share | -0.77 | -0.52 | -0.92 | -0.25 | -1.5 | |
Free cash flow per share | -0.81 | -0.52 | -0.92 | -0.26 | -1.52 | |
Cash per share | 6.64 | 5.79 | 4.92 | 4.69 | 18.16 | |
Book value per share | 1.15 | 0.71 | 0.23 | -0.49 | 1.3 | |
Tangible book value per share | -7.95 | -8.21 | -8.7 | -3.1 | -30.25 | |
Share holders equity per share | 1.15 | 0.71 | 0.23 | -0.49 | 1.3 | |
Interest debt per share | 0.3 | 2.26 | 2.26 | 2.3 | 17.14 | |
Market cap | 458.22M | 496.29M | 939.36M | 869.62M | 336.78M | |
Enterprise value | 395.32M | 485.62M | 1.04B | 964.3M | 814.21M | |
P/E ratio | 0.35 | -2.83 | -3.17 | -1.82 | 1.74 | |
Price to sales ratio | 5.61 | 7.96 | 17.67 | 13.63 | 5.7 | |
POCF ratio | -4.35 | -6.97 | -7.46 | -25.82 | -5.98 | |
PFCF ratio | -4.13 | -6.93 | -7.45 | -24.61 | -5.9 | |
P/B Ratio | 2.91 | 5.11 | 29.66 | -12.99 | 6.87 | |
PTB ratio | 2.91 | 5.11 | 29.66 | -12.99 | 6.87 | |
EV to sales | 4.84 | 7.79 | 19.49 | 15.11 | 13.78 | |
Enterprise value over EBITDA | 1.71 | -34.81 | -25.33 | -19.13 | 30.24 | |
EV to operating cash flow | -3.75 | -6.82 | -8.23 | -28.63 | -14.45 | |
EV to free cash flow | -3.56 | -6.78 | -8.22 | -27.29 | -14.27 | |
Earnings yield | 0.72 | -0.09 | -0.08 | -0.14 | 0.14 | |
Free cash flow yield | -0.24 | -0.14 | -0.13 | -0.04 | -0.17 | |
Debt to equity | 2.16 | 2.9 | 8.88 | -3.69 | 12.97 | |
Debt to assets | 0.14 | 0.13 | 0.13 | 0.12 | 0.31 | |
Net debt to EBITDA | -0.27 | 0.76 | -2.37 | -1.88 | 17.73 | |
Current ratio | 3.91 | 3.6 | 3.57 | 3.14 | 3.08 | |
Interest coverage | 0.14 | -2.46 | -1.78 | -0.76 | -9.4 | |
Income quality | -0.32 | 1.6 | 1.7 | 0.28 | -1.17 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.51 | 0.17 | 0.32 | 0.24 | 0.73 | |
Research and developement to revenue | 1.15 | 1.33 | 1.07 | 0.99 | 1.36 | |
Intangibles to total assets | 0.52 | 0.55 | 0.57 | 0.17 | 0.59 | |
Capex to operating cash flow | 0.05 | 0.01 | 0 | 0.05 | 0.01 | |
Capex to revenue | -0.07 | -0.01 | 0 | -0.03 | -0.01 | |
Capex to depreciation | -2.2 | -0.15 | -0.03 | -0.61 | -0.34 | |
Stock based compensation to revenue | 0.04 | 0.03 | 0.2 | 0 | -0.03 | |
Graham number | 7.91 | 2.26 | 1.68 | 3.11 | 6.14 | |
ROIC | -0.05 | -0.16 | -0.2 | -0.24 | -0.12 | |
Return on tangible assets | 0.29 | -0.04 | -0.08 | -0.07 | 0.06 | |
Graham Net | -9.05 | -9.25 | -9.79 | -10.59 | -32.75 | |
Working capital | 810.69M | 685.68M | 621.17M | 543.76M | 549.71M | |
Tangible asset value | -1.09B | -1.12B | -1.19B | -424M | -1.14B | |
Net current asset value | -1.15B | -1.18B | -1.25B | -1.37B | -1.16B | |
Invested capital | 2.16 | 2.9 | 8.88 | -3.69 | 12.97 | |
Average receivables | 110.23M | 95.21M | 82.12M | 72.27M | 50.5M | |
Average payables | 117.6M | 93.9M | 134.52M | 118.39M | 72.67M | |
Average inventory | 26.69M | 29.76M | 53.5M | 71.13M | 66.3M | |
Days sales outstanding | 123.82 | 112.73 | 145.9 | 82.32 | 64.98 | |
Days payables outstanding | 225.17 | 639.98 | 1.4K | 697.12 | 175.54 | |
Days of inventory on hand | 141.55 | 151.29 | 838.24 | 420.39 | 383.79 | |
Receivables turnover | 0.73 | 0.8 | 0.62 | 1.09 | 1.39 | |
Payables turnover | 0.4 | 0.14 | 0.06 | 0.13 | 0.51 | |
Inventory turnover | 0.64 | 0.59 | 0.11 | 0.21 | 0.23 | |
ROE | 2.09 | -0.45 | -2.34 | 1.79 | 0.98 | |
Capex per share | -0.04 | 0 | 0 | -0.01 | -0.02 |
MOR Frequently Asked Questions
What is MorphoSys AG stock symbol ?
MorphoSys AG is a DE stock and trading under the symbol MOR
What is MorphoSys AG stock quote today ?
MorphoSys AG stock price is $18.13 today.
Is MorphoSys AG stock public?
Yes, MorphoSys AG is a publicly traded company.